Stock comparison
Galapagos N.V.
Halozyme Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GLPG
Galapagos N.V.
Market cap
$1.81B
Sector
Healthcare
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GLPG | HALO | Winner |
|---|---|---|---|
| Warren Buffett | 41D | 79B | HALO |
| Benjamin Graham | 28F | 83A | HALO |
| Philip Fisher | 56C | 65B | HALO |
| Peter Lynch | 76B | 53D | GLPG |
| Joel Greenblatt | 39D | 40D | HALO |
| Charlie Munger | 46D | 80C | HALO |
| Terry Smith | 46D | 84A | HALO |
Side-by-side metrics
| Metric | GLPG | HALO |
|---|---|---|
| Market cap | $1.81B | $8.1B |
| P/E (TTM) | 3.1x | 24.0x |
| EV/EBIT | 2.9x | 10.2x |
| ROIC (TTM) | 17.67% | 23.65% |
| Gross margin | 98.01% | 81.24% |
| Net margin | 46.83% | 23.13% |
| Revenue CAGR 5y | 23.07% | 33.23% |
| EPS CAGR 5y | - | -1.98% |
| Debt / Equity | 0.0x | 1.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GLPG leads on
- Debt / Equity0.0xvs 1.0x+100%
- P/E (TTM)3.1xvs 24.0x+87%
- EV/EBIT2.9xvs 10.2x+72%
- Net margin46.83%vs 23.13%+51%
HALO leads on
- Market cap$8.1Bvs $1.81B+78%
- Revenue CAGR 5y33.23%vs 23.07%+31%
- ROIC (TTM)23.65%vs 17.67%+25%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.